Effects of moxibustion on patients with knee osteoarthritis

Not Applicable

Completed

• Conditions: Knee osteoarthritis; Musculoskeletal Diseases; Gonarthrosis [arthrosis of knee]

• Registration Number: ISRCTN68475405
• Lead Sponsor: Shanghai University of Traditional Chinese Medicine (China)

Brief Summary

2014 results in http://www.ncbi.nlm.nih.gov/pubmed/24962039 2015 results in http://www.ncbi.nlm.nih.gov/pubmed/25688277 2020 results in https://pubmed.ncbi.nlm.nih.gov/31446581/ (added 17/12/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2012-04-30
• Study Start: 2014-04-24
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

1. Male or female, 45 or older, with knee osteoarthritis diagnosed according to American College of Rheumatology criteria, including radiographic evidence of at least one osteophyte at the tibiofemoral joint in one or both knees (Kellgren?Lawrence score 2 or 3)
2. Pain score of at least 3 points on a 10-point visual analogue scale for most days during the previous month
3. Willingness to sign the consent form and be randomly assigned into either a treatment or a placebo group

Exclusion Criteria

1. Presence of serious medical conditions that preclude participation in the study
2. Intra-articular corticosteroid or hyaluronate injections, knee surgery, or use of topical capsaicin cream during the preceding 6 months
3. Previous experience with moxibustion
4. Planned events such as knee replacement that would interfere with participation in all 24 weeks of the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
WOMAC (VAS3.1) Questionnaire was applied to assess the therapeutic effects in terms of joint pain, stiffness, and functional disorder of the participants at 3 weeks and 6 weeks after the treatment initiation, and the long-term effects were also assessed at 12, and 24 weeks after baseline

Secondary Outcome Measures

Name	Time	Method
<br> 1. Short Form 36 (SF-36) component scales were used to assess health-related quality of life at baseline, week 3, week 6 and week 12<br> 2. The 50-yard walking time was assessed and recorded at baseline and week 6 to observe the improvement in walking<br>